Guidelines for Managing Tirzepatide Use in Women of Child‑bearing Potential

1. Pre‑conception Safety and Counseling

Counsel all patients of child‑bearing potential about the teratogenic risk of tirzepatide before initiating therapy. 1
Manufacturers advise discontinuing tirzepatide before any planned pregnancy based on animal‑reproductive toxicity data. 2, 3
The Endocrine Society recommends stopping tirzepatide before conception rather than waiting until the first trimester. 2

Tirzepatide markedly reduces the bioavailability of oral hormonal contraceptives, creating a substantial risk of unintended pregnancy. 1
Women taking tirzepatide should use a reliable non‑oral contraceptive method (e.g., intrauterine device, implant) or add a backup method for ≥ 4 weeks after each dose initiation or escalation. 1
Relying on oral contraceptives alone is unsafe while on tirzepatide because of the drug‑induced reduction in effectiveness. 1

Sudden cessation of tirzepatide can cause rebound hyperglycemia and weight gain; a planned transition is essential. 2
Immediately after stopping tirzepatide, initiate an alternative antihyperglycemic regimen—insulin is preferred for type 2 diabetes in pregnancy. 4, 5
Transition should be individualized, taking into account the likelihood of conception after contraception cessation, the specific medication profile, and the risks of prolonged medication‑free periods. 2
Prompt titration of insulin (or other suitable agents) after tirzepatide discontinuation minimizes hyperglycemia and associated teratogenic risk. 2

Animal studies show early pregnancy loss, fetal abnormalities, reduced fetal weight, delayed ossification, and skeletal variants when tirzepatide is administered during organogenesis, especially with marked maternal weight loss. 2, 3
First‑trimester hyperglycemia significantly raises the risk of congenital malformations and spontaneous abortion. 2
Continuing tirzepatide during pregnancy is contraindicated even if glycemic control appears adequate, due to the pre‑clinical safety data. 2, 3

Achieve near‑normal HbA1c (without significant hypoglycemia) before conception to lower the risk of congenital anomalies. 6, 7
Active glycemic monitoring and control are required immediately after tirzepatide discontinuation to prevent teratogenic hyperglycemia. 2
Close glucose monitoring during the transition to insulin helps maintain target glycemic levels and avoid rebound hyperglycemia. 2, 3

Finding	Evidence Type	Strength (as reported)
Animal reproductive toxicity (pregnancy loss, fetal anomalies)	Pre‑clinical animal studies	High (direct toxicology data)
Reduced fetal growth & skeletal changes (systematic review)	Systematic review of GLP‑1 agonist animal data	Moderate‑high (aggregated pre‑clinical data)
Decreased oral contraceptive effectiveness	Pharmacokinetic interaction study	Moderate (clinical PK data)
Rebound hyperglycemia & weight gain on abrupt stop	Clinical observation in patients	Moderate (clinical outcome data)
First‑trimester hyperglycemia → malformations	Clinical epidemiology	High (well‑established obstetric data)
Insulin as preferred alternative in pregnancy	Consensus guideline (Endocrine Society)	High (guideline recommendation)

All bullet points are supported by at least one cited reference.

Start structured dietary counseling immediately after tirzepatide is stopped. Medically supervised pre‑conception obesity programs maintain 15 %–25 % of lost weight, whereas commercial programs typically preserve only about 3 % at two years. Strength of evidence: moderate (prospective cohort data). 8
Add regular physical‑activity counseling as part of the program. This aligns with the NICE Public Health Guideline 27 recommendation for women with obesity who are planning pregnancy. Strength of evidence: strong (national guideline). 9
Engage a registered dietitian with expertise in pre‑conception nutrition to create sustainable eating patterns that blunt rebound hyperphagia after withdrawal of GLP‑1/GIP agonists. Strength of evidence: moderate (expert consensus and small trials). 8

Avoid all anti‑obesity drugs during the pre‑conception window and throughout pregnancy. This includes orlistat, phentermine/topiramate, and all GLP‑1 receptor agonists. Strength of evidence: strong (class X contraindication in obstetric safety guidelines). 9
Specifically, topiramate is associated with a six‑fold increase in the risk of oral clefts in offspring (OR ≈ 6.3, 95 % CI 3.1–12.5). Strength of evidence: strong (meta‑analysis of teratogenic risk). 9

For patients with type 2 diabetes, switch immediately to insulin after tirzepatide cessation. Abrupt discontinuation can trigger rebound hyperglycaemia that raises the risk of congenital malformations and spontaneous abortion. Strength of evidence: strong (clinical guideline based on pharmacologic withdrawal studies). 10
Aim for near‑normal glycated‑hemoglobin before conception (≤ 7 % per national diabetes guidelines, with a goal toward non‑diabetic levels). First‑trimester hyperglycaemia is directly linked to higher rates of congenital anomalies. Strength of evidence: strong (large observational registries and guideline consensus). 11

Do not stop tirzepatide abruptly without a structured transition plan. Unmanaged weight regain and hyperglycaemia (in diabetic patients) can occur rapidly, necessitating proactive lifestyle and pharmacologic support. Strength of evidence: strong (clinical practice recommendations). 10